SHSE:600196

Stock Analysis Report

Shanghai Fosun Pharmaceutical (Group)

Executive Summary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally.

Snowflake

Fundamentals

Established dividend payer and good value.


Similar Companies

Share Price & News

How has Shanghai Fosun Pharmaceutical (Group)'s share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.08%

600196

0.5%

CN Pharmaceuticals

-1.3%

CN Market


1 Year Return

-11.3%

600196

25.7%

CN Pharmaceuticals

25.5%

CN Market


Shareholder returns

600196IndustryMarket
7 Day0.08%0.5%-1.3%
30 Day-9.5%-0.3%-3.0%
90 Day-4.3%9.1%2.6%
1 Year-10.2%-11.3%27.2%25.7%27.7%25.5%
3 Year12.9%9.0%-7.0%-9.9%-11.1%-14.6%
5 Year42.9%34.3%32.9%26.6%38.2%30.0%

Price Volatility Vs. Market

How volatile is Shanghai Fosun Pharmaceutical (Group)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Shanghai Fosun Pharmaceutical (Group) undervalued compared to its fair value and its price relative to the market?

35.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: 600196 (CN¥25.34) is trading below our estimate of fair value (CN¥39.38)

Significantly Undervalued: 600196 is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: 600196 is good value based on its PE Ratio (24.3x) compared to the Pharmaceuticals industry average (29.8x).

PE vs Market: 600196 is good value based on its PE Ratio (24.3x) compared to the CN market (31.5x).


Price to Earnings Growth Ratio

Low PEG Ratio: 600196 is poor value based on its PEG Ratio (1.9x)


Price to Book Ratio

PB vs Industry: 600196 is good value based on its PB Ratio (2.3x) compared to the CN Pharmaceuticals industry average (2.5x).


Next Steps

Future Growth

How is Shanghai Fosun Pharmaceutical (Group) forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

12.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600196's forecast earnings growth (12.8% per year) is above the savings rate (2.7%).

Earnings vs Market: 600196's earnings (12.8% per year) are forecast to grow slower than the CN market (18.4% per year).

High Growth Earnings: 600196's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600196's revenue (16.7% per year) is forecast to grow faster than the CN market (15.2% per year).

High Growth Revenue: 600196's revenue (16.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Shanghai Fosun Pharmaceutical (Group) performed over the past 5 years?

6.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 600196's earnings have grown by 6.3% per year over the past 5 years.

Accelerating Growth: 600196's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 600196 had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3.3%).


Return on Equity

High ROE: 600196's Return on Equity (9%) is considered low.


Return on Assets

ROA vs Industry: 600196's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 600196's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Shanghai Fosun Pharmaceutical (Group)'s financial position?


Financial Position Analysis

Short Term Liabilities: 600196's short term assets (CN¥18.4B) exceeds its short term liabilities (CN¥17.8B)

Long Term Liabilities: 600196's short term assets (18.4B) do not cover its long term liabilities (21.3B)


Debt to Equity History and Analysis

Debt Level: 600196's debt to equity ratio (68.9%) is considered high

Reducing Debt: 600196's debt to equity ratio has increased from 40.4% to 68.9% over the past 5 years.

Debt Coverage: 600196's debt is not well covered by operating cash flow (13.1%).

Interest Coverage: 600196 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is Shanghai Fosun Pharmaceutical (Group)'s current dividend yield, its reliability and sustainability?

1.26%

Current Dividend Yield


Dividend Yield vs Market

company1.3%marketbottom25%0.5%markettop25%1.9%industryaverage1.3%forecastin3Years1.8%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 600196's dividend (1.26%) is higher than the bottom 25% of dividend payers in the CN market (0.46%).

High Dividend: 600196's dividend (1.26%) is low compared to the top 25% of dividend payers in the CN market (1.93%).

Stable Dividend: 600196's dividends per share have been stable in the past 10 years.

Growing Dividend: 600196's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (30.7%), 600196's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 600196's dividends in 3 years are forecast to be well covered by earnings (28.5% payout ratio).


Next Steps

Management

What is the CEO of Shanghai Fosun Pharmaceutical (Group)'s salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Yifang Wu (50yo)

3.3yrs

Tenure

CN¥8,333,000

Compensation

Mr. Yifang Wu has been the Chief Executive Officer and President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since June 7, 2016. Mr. Wu serves as the President of Wanbang Biopharmaceuticals Co., Ltd ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Yifang's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

4.3yrs

Average Tenure

49.5yo

Average Age

Experienced Management: 600196's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

3.2yrs

Average Tenure

50yo

Average Age

Experienced Board: 600196's board of directors are considered experienced (3.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCN¥3,216,79417 Jan 19
Fosun International Holdings Ltd.
EntityCompany
Shares140,000
Max PriceCN¥22.98
BuyCN¥887,00010 Jan 19
Fosun International Holdings Ltd.
EntityCompany
Shares40,000
Max PriceCN¥22.17
BuyCN¥14,293,82609 Jan 19
Fosun International Holdings Ltd.
EntityCompany
Shares640,000
Max PriceCN¥22.33
BuyCN¥1,923,12431 Dec 18
Fosun International Holdings Ltd.
EntityCompany
Shares79,800
Max PriceCN¥24.10
BuyCN¥14,593,37231 Dec 18
Fosun International Holdings Ltd.
EntityCompany
Shares620,000
Max PriceCN¥23.54
BuyCN¥526,00007 Dec 18
Yifang Wu
EntityIndividual
Role
Chief Executive Officer
President
Shares20,000
Max PriceCN¥26.30

Ownership Breakdown


Management Team

  • Fang Yao (50yo)

    Executive Director

    • Tenure: 9.3yrs
    • Compensation: CN¥9.90m
  • Qiyu Chen (47yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: CN¥14.25m
  • Kexin Wang (55yo)

    Senior Vice President

    • Tenure: 0yrs
  • Xiaohui Guan (48yo)

    Senior VP & CFO

    • Tenure: 4.3yrs
  • Yifang Wu (50yo)

    President

    • Tenure: 3.3yrs
    • Compensation: CN¥8.33m
  • Cheng Wang (56yo)

    Senior Vice President

    • Tenure: 0yrs
  • Biao Zhou (49yo)

    Senior Vice President

    • Tenure: 5.7yrs
  • Yuqing Chen (44yo)

    Senior Vice President

    • Tenure: 0yrs
  • Donghua Wang (50yo)

    VP and GM of Public Affairs Department & Administration Department

    • Tenure: 0yrs
  • Xiaoxian Dong (38yo)

    Senior VP

    • Tenure: 0yrs

Board Members

  • Kelvin Wong (59yo)

    Independent Non-Executive Director

    • Tenure: 4.3yrs
    • Compensation: CN¥300.00k
  • Fang Yao (50yo)

    Executive Director

    • Tenure: 9.3yrs
    • Compensation: CN¥9.90m
  • Guliang Tang (56yo)

    Independent Non-Executive Director

    • Tenure: 0.3yrs
  • Qiyu Chen (47yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: CN¥14.25m
  • Xiaoliang Xu (46yo)

    Non Executive Director

    • Tenure: 0.3yrs
  • Yifang Wu (50yo)

    President

    • Tenure: 3.3yrs
    • Compensation: CN¥8.33m
  • Xian Jiang (64yo)

    Independent Non-Executive Director

    • Tenure: 4.3yrs
    • Compensation: CN¥300.00k
  • Robin Wang (40yo)

    Non-Executive Director

    • Tenure: 3.3yrs
  • Haining Mu (46yo)

    Non-Executive Director

    • Tenure: 1.3yrs
  • Qian Ren (50yo)

    Chairman of Supervisory Committee

    • Tenure: 1.8yrs

Company Information

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Ticker: 600196
  • Exchange: SHSE
  • Founded: 1994
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥61.923b
  • Shares outstanding: 2.56b
  • Website: https://www.fosunpharma.com

Number of Employees


Location

  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Building A
  • No. 1289 Yishan Road
  • Shanghai
  • 200233
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
600196SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYAug 1998
600196XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect)YesDomestic SharesCNCNYAug 1998
2196SEHK (The Stock Exchange of Hong Kong Ltd.)Foreign Shares-Foreign ListedHKHKDOct 2012
SFOS.FOTCPK (Pink Sheets LLC)Foreign Shares-Foreign ListedUSUSDOct 2012
08HHBST (Boerse-Stuttgart)Foreign Shares-Foreign ListedDEEUROct 2012
2196SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDOct 2012
2196SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDOct 2012

Biography

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in fi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 14:35
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.